Clinical Trials · NCT07527910
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Enrollment
- 204
- Start date
- May 2026
- Locations
- 5 sites, United States
- Primary endpoint
- Percent change in liver fat